MacroCure

Therapeutic Platform for Hard-to-Heal Wounds

Acquired (Inactive) by Leap Therapeutics on Jan 2017 - closed due to acquisition

Company Overview

Snapshot

Founded in January 2008, MacroCure operates with 1–10 employees. The company raised a total of $102 million across 3 funding rounds from 4 investors. MacroCure was acquired by Leap Therapeutics in January 2017.

Business overview

MacroCure Ltd is a clinical-stage biopharmaceutical company focused on developing a novel therapeutic platform for chronic and hard-to-heal wounds, such as diabetic foot ulcers and venous leg ulcers. The company's core technology involves injecting the human body's own wound-healing and regenerative components directly into the wound. Its lead product candidate, CureXcell, is a combination of activated living human white blood cells designed to facilitate healing and stimulate wound closure. MacroCure serves the healthcare and life sciences sectors, specifically targeting pharmaceuticals and chronic patient care.

Strategic signal

In January 2017, MacroCure completed a merger with Leap Therapeutics. This strategic move indicates a significant consolidation within the biopharmaceutical sector, allowing for potential synergies in research, development, and market reach for wound treatment solutions. For investors, this signals a shift in the company's operational structure and future strategic direction under a larger entity.

Company Intelligence Q&A

What was a key strategic event for MacroCure in early 2017?: In January 2017, MacroCure and Leap Therapeutics completed their merger, leading to MacroCure's acquisition and subsequent delisting from NASDAQ in January 2018.
When did MacroCure announce its definitive merger agreement with Leap Therapeutics?: MacroCure and Leap Therapeutics announced their definitive merger agreement in August 2016.
What was the outcome of a significant clinical trial for MacroCure in August 2015?: In August 2015, MacroCure's share price plunged following a trial failure, as reported by Globes.co.il.
Which investors participated in MacroCure's May 2012 funding round?: In May 2012, MacroCure received funding from Rainfall Ventures and Jerusalem Global Ventures.
Which investors participated in MacroCure's April 2011 funding round?: In April 2011, MacroCure received funding from Viola Growth and Docor International Management.

External links

MacroCure — full profile (machine-readable)

MacroCure Ltd is a clinical-stage biopharmaceutical company focused on developing a novel therapeutic platform to address chronic and hard-to-heal wounds, such as diabetic foot ulcers and venous leg ulcers. The company's approach is to treat chronic and other hard-to-heal wounds by injecting the human body's own wound-healing and regenerative components directly into the wound. MacroCure's lead product candidate, CureXcell, is a combination of living human white blood cells that have been activated to facilitate the healing process and stimulate wound closure. CureXcell's two phase 3 double-blind clinical trials target a broad indication for the treatment of diabetic foot ulcers and venous leg ulcers. MacroCure already has product approval for CureXcell as a medical device in Israel for the treatment of chronic and other hard-to-heal wounds. CureXcell has effectively treated more than 5,000 patients in commercial or clinical study settings in Israel. In 2017, MacroCure Ltd merged into Leap Therapeutics, Inc.

Facts
Name	MacroCure
One-liner	Therapeutic Platform for Hard-to-Heal Wounds
Type	Startup
Founded	2008
Employees	1-10
Employees (exact)	9
HQ / location	Petah Tikva, Ha-Sivim St 25, Petah Tikva, Israel, Center District
Product stage	Clinical Trial
LinkedIn	https://www.linkedin.com/company/566839
Crunchbase	macrocure
IL Registrar	514083765

Facts

Name

MacroCure

One-liner

Therapeutic Platform for Hard-to-Heal Wounds

Type

Startup

Founded

2008

Employees

1-10

Employees (exact)

HQ / location

Petah Tikva, Ha-Sivim St 25, Petah Tikva, Israel, Center District

Product stage

Clinical Trial

https://www.linkedin.com/company/566839

Crunchbase

macrocure

IL Registrar

514083765

Classification
Sectors	Health Tech & Life Sciences, Pharma & Medical Biotechnology, Drugs Discovery & Development
Core technology	Biologicals, Cells
Target customers	Healthcare & Life Sciences, Life Sciences, Pharmaceuticals
Business models	B2B
Tags	biotechnology, ulcers, medical-technologies, regenerative-medicine, biopharmaceutical, cell-therapy, bioprocess, chronic-patients

Classification

Sectors

Health Tech & Life Sciences, Pharma & Medical Biotechnology, Drugs Discovery & Development

Core technology

Biologicals, Cells

Target customers

Healthcare & Life Sciences, Life Sciences, Pharmaceuticals

Business models

B2B

Date	Round	Amount	Investors
May 2012	A Round	$35M	Rainfall Ventures, Jerusalem Global Ventures
Apr 2011	Undisclosed Round	$13M	Viola Growth, Docor International Management

Date	Type	Amount
Jan 2018	exit	Undisclosed
Jan 2017	exit	Undisclosed
Aug 2014	exit	Undisclosed

Date	Source	Summary
Dec 3, 2017	www.globes.co.il	Macrocure raises $54m in Nasdaq IPO
Apr 17, 2017	www.physiciansnews.com	Innovation Could Spur Much-Needed Advances in Treating Diabetic Foot Ulcers
Apr 4, 2017	www.clinicaltrials.gov	Search of: curexcell - List Results - ClinicalTrials.gov
Jan 24, 2017	www.prnewswire.com	Macrocure and Leap Therapeutics Complete Merger
Aug 29, 2016	www.prnewswire.com	Leap Therapeutics and Macrocure Announce Definitive Merger Agreement
Aug 23, 2015	www.globes.co.il	Macrocure share price plunges after trial failure
Nov 12, 2014	www.thestreet.com	Macrocure CEO: Wall Street Catching On as Pivotal Phase 3 Nears

MacroCure

Company Overview

Snapshot

Business overview

Strategic signal

Company Intelligence Q&A

External links

Generate Slim Page